Clinical trial NCT01414920: Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
Official title: A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination With Sitagliptin 100 mg in Subjects With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus, Type 2
Keywords: Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2011-08-11
Enrollment: 368
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).

Detailed description: TAK-875 is being developed at Takeda Global Research and Development, Inc. as an adjunct to diet and exercise to improve glycemic control in patients with T2DM.

Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4) approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.

This study will investigate the effects of the combination of TAK-875 with a DDP-4 inhibitor on glycosylated hemoglobin reduction.

Eligibility criteria: Inclusion Criteria:

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
3. The participant has either:

   * A historical diagnosis of Type 2 Diabetes (T2DM) without the chronic use (defined as \>7 days) of anti-diabetic therapy within 8 weeks prior to Screening, and with at least an 8-week documented history of a diet and exercise plan at Screening OR,
   * A historical diagnosis of T2DM and stable on at least 1500 mg per day (or maximum tolerated dose) of metformin as monotherapy for at least 8 weeks at Screening. Participants on a stable dose of metformin who enter the study will continue on the same dose of metformin throughout the duration of the study.
4. The participant is a man or woman and aged 18 to 80 years, inclusive.
5. The participant's body mass index (BMI) (kg/m2) at Screening is ≥23 and ≤45.
6. The participant has an glycosylated hemoglobin (HbA1c) level at Screening between 7.5% and 10.0%, inclusive, if on metformin and between 7.5% to 10.9%, inclusive, if treated with diet and exercise alone.
7. The participant has a fasting plasma glucose level \<14.4 mmol/L (\<260 mg/dL), at Screening.
8. The participant has a fasting C-peptide concentration ≥0.26 nmol/L (≥0.8 ng/mL) at Screening.
9. If the participant takes any chronic, non-excluded medications, the dose of these medications must have been stable (no change in dose or drug) for at least 4 weeks prior to Screening.
10. The participant is able and willing to monitor their glucose levels with a home glucose monitor and consistently record his or her own blood glucose concentrations according to the given instructions.
11. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.
12. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
13. A female participant of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening (Visit 1) and at Placebo Run-in (Visit 2). A negative urine HCG pregnancy test is also required at Randomization (Visit 3), prior to administration of the first dose of double-blind study medication.
14. The participant's compliance with single-blind study medication during the run-in phase is at least 80% and does not exceed 120% based on tablet counts performed by the study staff.

Exclusion Criteria:

1. The participant has received any investigational compound within 4 weeks prior to Screening.
2. The participant has been enrolled in a previous TAK-875 study.
3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
4. The participant has a history of hypersensitivity or allergies to TAK-875 or sitagliptin, or their excipients.
5. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the Screening visit.
6. The participant has a history of cancer that has been in remission for \<5 years prior to Screening (a history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed).
7. The participant has systolic blood pressure ≥150 mm Hg or diastolic pressure ≥90 mm Hg at Screening (Visit 1) or Baseline (Visit 3) (as confirmed by repeat measurement 30 minutes after initial measurement).
8. The participant has a creatine phosphokinase (CPK) level ≥5x the upper limit of normal (ULN) at Screening.
9. The participant has a hemoglobin level of ≤12 g/dL (120 gm/L) for men and ≤10 g/dL (100 gm/L) for women at Screening.
10. The participant has ALT and/or AST levels ≥2.5x ULN at Screening.
11. The participant has a total bilirubin level \> ULN at Screening.
12. The participant has a serum triglyceride concentration ≥4.5 mmol/L (≥400 mg/dL) at Screening.
13. The participant has an estimated glomerular filtration rate ≤60mL/min using the Modification of Diet in Renal Disease (MDRD) equation at Screening.
14. The participant has a documented history or concurrent signs of uncontrolled (not euthyroid) thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules).
15. The participant has a history of pancreatitis.
16. The participant has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
17. The participant has a history of gastric bypass surgery or has diabetic gastroparesis that in the investigator's opinion is moderate or severe and hence may impair absorption of study medication.
18. The participant has had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within 6 months prior or at Screening.
19. The participant has a history of any hemoglobinopathy that may affect determination of HbA1c.
20. The participant has a positive test result for hepatitis B surface antigen and antibody to hepatitis C virus, and/or has known history of human immunodeficiency virus at Screening.
21. The participant has donated or received any blood products within 12 weeks prior to Screening.
22. The participant received medication prior to Screening as listed in the excluded Medications section.
23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate an ova during such time period.
24. If male, the participant intends to donate sperm during the course of this study or for 30 days thereafter.
25. The participant has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the participant according to the protocol.

Primary outcomes:
measure: Change from Baseline in Glycosylated Hemoglobin (HbA1c)
timeFrame: Baseline and Week 12.
Secondary outcomes:
measure: Change from Baseline in Fasting Plasma Glucose
timeFrame: Baseline and Week 12.
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Brimingham
country: United States
state: Alabama
city: Chandler
country: United States
state: Arizona
city: Glendale
country: United States
state: Arizona
city: Green Valley
country: United States
state: Arizona
city: Mesa
country: United States
state: Arizona
city: Tempe
country: United States
state: Arizona
city: Tucson
country: United States
state: Arizona
city: Buena Park
country: United States
state: California
city: Irvine
country: United States
state: California
city: Norwalk
country: United States
state: California
city: Paramount
country: United States
state: California
city: Rancho Cucamonga
country: United States
state: California
city: San Ramon
country: United States
state: California
city: Spring Valley
country: United States
state: California
city: Vista
country: United States
state: California
city: Walnut Creek
country: United States
state: California
city: Westlake Village
country: United States
state: California
city: Colorado Springs
country: United States
state: Colorado
city: Lakewood
country: United States
state: Colorado
city: Brandon
country: United States
state: Florida
city: Clearwater
country: United States
state: Florida
city: DeLand
country: United States
state: Florida
city: Hallandale Beach
country: United States
state: Florida
city: Hialeah
country: United States
state: Florida
city: Jupiter
country: United States
state: Florida
city: Longwood
country: United States
state: Florida
city: Miami Lakes
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
city: Pembroke Pines
country: United States
state: Florida
city: St Petersburg
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Roswell
country: United States
state: Georgia
city: Suwanee
country: United States
state: Georgia
city: Boise
country: United States
state: Idaho
city: Chicago
country: United States
state: Illinois
city: Valparaiso
country: United States
state: Indiana
city: Crestview Hills
country: United States
state: Kentucky
city: Lexington
country: United States
state: Kentucky
city: Louisville
country: United States
state: Kentucky
city: Bangor
country: United States
state: Maine
city: Elkridge
country: United States
state: Maryland
city: Brockton
country: United States
state: Massachusetts
city: Chelsea
country: United States
state: Michigan
city: Kalamazoo
country: United States
state: Michigan
city: Olive Branch
country: United States
state: Mississippi
city: Berlin
country: United States
state: New Jersey
city: Margate
country: United States
state: New Jersey
city: Toms River
country: United States
state: New Jersey
city: Brooklyn
country: United States
state: New York
city: Buffalo
country: United States
state: New York
city: Calabash
country: United States
state: North Carolina
city: Fuquay-Varina
country: United States
state: North Carolina
city: Morehead City
country: United States
state: North Carolina
city: Winston-Salem
country: United States
state: North Carolina
city: Akron
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Lyndhurst
country: United States
state: Ohio
city: Marion
country: United States
state: Ohio
city: Willoughby Hills
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Portland
country: United States
state: Oregon
city: Broomall
country: United States
state: Pennsylvania
city: Feasterville
country: United States
state: Pennsylvania
city: Fleetwood
country: United States
state: Pennsylvania
city: Cranston
country: United States
state: Rhode Island
city: Chattanooga
country: United States
state: Tennessee
city: Crossville
country: United States
state: Tennessee
city: Kingsport
country: United States
state: Tennessee
city: Nashville
country: United States
state: Tennessee
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Irving
country: United States
state: Texas
city: North Richland Hills
country: United States
state: Texas
city: Pearland
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Seattle
country: United States
state: Washington
Study officials:
affiliation: Takeda
name: Sr. Medical Director Clinical Science
role: STUDY_DIRECTOR
References: